Lantern Pharma Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Lantern Pharma Inc. (LTRN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$243.05 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $461.98K, a 26.35% decline year-over-year.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$705.02K.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $467.00K, a 36.71% decline year-over-year.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$806.92K.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $271.81K, a 83.39% decline from fiscal 2024.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.64M.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$236.18K, a 140.70% decline from fiscal 2022.
- Lantern Pharma Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $580.36K, a 64.22% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $461.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$243.05K 10-Q · filed 2026-08-14 | $223.95K derived: sum of 3 quarters · filed 2026-08-14 | -$582.97K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$705.02K 10-Q · filed 2026-05-15 | -$238.03K derived: sum of 2 quarters · filed 2026-05-15 | -$1.04M derived: sum of 3 quarters · filed 2026-05-15 | -$417.66K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$339.92K derived: sum of 2 quarters · filed 2026-03-30 | $287.36K derived: sum of 3 quarters · filed 2026-08-14 | $271.81K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$806.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$179.64K derived: sum of 2 quarters · filed 2026-08-14 | -$195.19K 10-Q · filed 2025-11-12 | $542.69K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $627.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $611.73K 10-Q · filed 2026-08-14 | $1.35M derived: sum of 3 quarters · filed 2026-08-14 | $316.28K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$15.55K 10-Q · filed 2026-05-15 | $722.33K derived: sum of 2 quarters · filed 2026-05-15 | -$311.00K derived: sum of 3 quarters · filed 2026-05-15 | $350.18K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $737.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$295.45K derived: sum of 2 quarters · filed 2026-03-30 | $365.73K derived: sum of 3 quarters · filed 2026-03-30 | $1.64M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$372.15K derived: sum of 2 quarters · filed 2025-11-12 | $898.56K 10-Q · filed 2025-11-12 | $1.32M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $661.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.93M 10-Q · filed 2025-08-13 | $2.35M derived: sum of 3 quarters · filed 2025-08-13 | $1.58M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-15 | $1.69M derived: sum of 2 quarters · filed 2025-05-15 | $922.75K derived: sum of 3 quarters · filed 2025-05-15 | $1.10M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $419.92K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$347.95K derived: sum of 2 quarters · filed 2025-03-27 | -$168.88K derived: sum of 3 quarters · filed 2025-03-27 | -$236.18K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$767.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$588.80K derived: sum of 2 quarters · filed 2024-11-07 | -$656.10K 10-Q · filed 2024-11-07 | -$961.74K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $179.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $111.77K 10-Q · filed 2024-08-08 | -$193.87K derived: sum of 3 quarters · filed 2024-08-08 | -$2.33M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$67.30K 10-Q · filed 2024-05-09 | -$372.94K derived: sum of 2 quarters · filed 2024-05-09 | -$2.51M derived: sum of 3 quarters · filed 2024-05-09 | -$229.46K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$305.64K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$2.44M derived: sum of 2 quarters · filed 2024-03-18 | -$162.16K derived: sum of 3 quarters · filed 2024-03-18 | $580.36K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $143.47K derived: sum of 2 quarters · filed 2023-11-08 | $886.00K 10-Q · filed 2023-11-08 | $2.37M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.02M 10-Q · filed 2023-08-09 | $4.51M derived: sum of 3 quarters · filed 2023-08-09 | $3.97M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $742.52K 10-Q · filed 2023-05-09 | $2.23M derived: sum of 2 quarters · filed 2023-05-09 | $1.69M derived: sum of 3 quarters · filed 2023-05-09 | $2.20M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $944.47K derived: sum of 2 quarters · filed 2023-03-20 | $1.46M derived: sum of 3 quarters · filed 2023-03-20 | $1.62M 10-K · filed 2023-03-20 |
| 2021-09-30 | -$543.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$29.92K derived: sum of 2 quarters · filed 2022-11-07 | $134.15K 10-Q · filed 2022-11-07 | -$179.69K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $513.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $677.62K 10-Q · filed 2022-08-08 | $363.78K derived: sum of 3 quarters · filed 2022-08-08 | $733.04K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $164.07K 10-Q · filed 2022-05-03 | -$149.76K derived: sum of 2 quarters · filed 2022-05-03 | $219.50K derived: sum of 3 quarters · filed 2022-05-03 | $322.27K derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$313.84K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $55.42K derived: sum of 2 quarters · filed 2022-03-10 | $158.20K derived: sum of 3 quarters · filed 2022-03-10 | $117.17K 10-K · filed 2022-03-10 |
| 2020-09-30 | $369.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $472.04K derived: sum of 2 quarters · filed 2021-11-01 | $431.00K 10-Q · filed 2021-11-01 | $499.19K derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $102.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $61.74K 10-Q · filed 2021-07-29 | $129.93K derived: sum of 3 quarters · filed 2021-07-29 | $209.99K derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | -$41.03K 10-Q · filed 2021-05-03 | $27.16K derived: sum of 2 quarters · filed 2021-05-03 | $107.21K derived: sum of 3 quarters · filed 2021-05-03 | |
| 2019-12-31 | $68.19K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $148.25K derived: sum of 2 quarters · filed 2021-03-10 | $372.66K 10-K · filed 2021-03-10 | |
| 2019-09-30 | $80.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $304.47K 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $224.42K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |